REGENXBIO (NASDAQ:RGNX) Price Target Cut to $34.00 by Analysts at HC Wainwright

REGENXBIO (NASDAQ:RGNX) had its target price cut by HC Wainwright from $36.00 to $34.00 in a research note published on Monday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for REGENXBIO’s Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.20) EPS, Q3 2025 earnings at ($1.20) EPS, Q4 2025 earnings at ($1.19) EPS and FY2025 earnings at ($4.80) EPS.

Several other equities research analysts also recently weighed in on RGNX. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. The Goldman Sachs Group downgraded REGENXBIO from a “buy” rating to a “neutral” rating and cut their price target for the stock from $38.00 to $14.00 in a report on Tuesday, February 11th. Raymond James assumed coverage on REGENXBIO in a report on Friday, February 7th. They set an “outperform” rating and a $27.00 price target on the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $30.00 price objective on shares of REGENXBIO in a report on Tuesday, January 21st. Finally, Chardan Capital reiterated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a report on Friday, March 14th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, REGENXBIO currently has an average rating of “Moderate Buy” and a consensus target price of $33.88.

REGENXBIO Trading Up 9.0 %

RGNX stock opened at $8.50 on Monday. The business’s fifty day moving average price is $7.28 and its 200 day moving average price is $8.93. REGENXBIO has a 12-month low of $5.62 and a 12-month high of $23.14. The company has a market capitalization of $421.13 million, a PE ratio of -1.69 and a beta of 1.35.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. The company had revenue of $21.21 million for the quarter, compared to the consensus estimate of $23.70 million. Research analysts predict that REGENXBIO will post -4.84 EPS for the current fiscal year.

Institutional Trading of REGENXBIO

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of REGENXBIO by 273.1% in the 4th quarter. GAMMA Investing LLC now owns 3,429 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 2,510 shares during the period. FMR LLC boosted its position in shares of REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 1,656 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in shares of REGENXBIO in the 4th quarter valued at about $54,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of REGENXBIO in the 4th quarter valued at about $79,000. Finally, Laurion Capital Management LP acquired a new stake in shares of REGENXBIO in the 4th quarter valued at about $79,000. 88.08% of the stock is owned by institutional investors and hedge funds.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.